Exclusive Interview with John Glick, MD

Tom Dilling, Alec Schwartz
University of Pennsylvania Cancer Center
Ultima Vez Modificado: 20 de mayo del 1996

Dr. Bunn: There are six new drugs which have been approved or are about to be approved for treating lung cancer and they're probably all six of them better than drugs which we've had in the past, and I think they will improve survival for patients with lung cancer.

I guess the second point is that the patients who have "earlier-stage" [lung cancer], if you give them chemotherapy with radiation or with surgery or all three together, it is providing better survival than what we had in the past with just surgery alone.

And the last thing you can tell your people is: Don't smoke!

OncoLink: Just to reiterate again for all our listeners and readers out there who were not at this talk....

Dr. Bunn: They're not here? I thought they were all here!

  • laugh
  • OncoLink: Yes, well....

    What were those six new drugs which you see as on the forefront?

    Dr. Bunn: There's two taxanes, paclitaxel and docetaxel, which some people call taxol and taxotere; there's two topoisomerase I inhibitors, irinotecan and topotecan; and then there's navelbine and gemcitabine (Gemzar®).

  • Keywords

    Click on any of these terms for more related articles

    Blogs

    Is Ayurveda the Answer to Women’s Health Issues?
    by The 4Wholeness Team
    September 01, 2015

    Related News

    Folic Acid Enrichment May Reduce Specific Pediatric Cancers

    May 22, 2012

    Postfortification of grains, decrease seen in Wilms tumor, primitive neuroectodermal tumor incidence


    Progression-Free Survival Not Tied to R-CHOP Dose Density

    Sep 21, 2011

    No significant difference for patients with indolent B-cell lymphoma treated with R-CHOP-14 or -21


    Increased rate likely due to rise in infections related to transrectal ultrasound-guided biopsy

    Mar 18, 2010

    Increased rate likely due to rise in infections related to transrectal ultrasound-guided biopsy